{"schema_version":"1","generated_at":"2026-11-07T19:57:08.576Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jennifer-cooperrider","json_url":"https://www.findmykol.com/kol/jennifer-cooperrider/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jennifer-cooperrider","name":"Jennifer Cooperrider","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Chicago","institution_url":"https://www.findmykol.com/institution/university-of-chicago","city":"Chicago","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1154841757","openalex":"A5006039568"},"summary":"Jennifer Cooperrider is an Oncology physician affiliated with University of Chicago. OpenAlex indexes 41 publications with 558 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":41,"cited_by_count":558,"h_index":10,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"GENZYME CORPORATION","program_year":2025,"amount_usd":101.38,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1154841757"},{"payer":"Adaptive Biotechnologies Corporation","program_year":2025,"amount_usd":82.18,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1154841757"},{"payer":"Adaptive Biotechnologies Corporation","program_year":2023,"amount_usd":31.13,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1154841757"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1154841757","source":"payments"},"prescribing":{"data_year":2020,"areas_total":4,"areas_shown":3,"areas":[{"area":"Cardiovascular","share_pct":76,"classes_total":5,"classes":[{"class":"Statin","setting":"prescribed","share_pct":25,"drugs":[{"name":"Atorvastatin Calcium","share_pct":100}],"max_beneficiaries":16},{"class":"ACE inhibitor","setting":"prescribed","share_pct":18.5,"drugs":[{"name":"Lisinopril","share_pct":64.9},{"name":"Enalapril Maleate","share_pct":35.1}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":9.5,"classes_total":1,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":9.5,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":7.5,"classes_total":1,"classes":[{"class":"Biguanide (metformin)","setting":"prescribed","share_pct":7.5,"drugs":[{"name":"Metformin Hcl","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2020,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":41,"shown":5,"withheld":36,"matched_by":"OpenAlex author record","recent":[{"title":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial","year":2026,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(26)00011-6","status":"verified"},{"title":"Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7517","status":"verified"},{"title":"Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015721","status":"verified"},{"title":"Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma","year":2025,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-025-02707-2","status":"verified"},{"title":"Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma","year":2025,"journal":"Blood Neoplasia","source_url":"https://doi.org/10.1016/j.bneo.2025.100124","status":"verified"}],"source":"works"},"contact":{"address_1":"5841 S MARYLAND AVE STE MC7082","city":"Chicago","state":"IL","zip":"606371465","phone":"773-795-0232","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1154841757","source":"identity"},"similar":[{"name":"Everett Vokes","slug":"everett-vokes","institution":"University of Chicago","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/everett-vokes","json_url":"https://www.findmykol.com/kol/everett-vokes/profile.json"},{"name":"Ralph Weichselbaum","slug":"ralph-weichselbaum","institution":"University of Chicago","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/ralph-weichselbaum","json_url":"https://www.findmykol.com/kol/ralph-weichselbaum/profile.json"},{"name":"Mary Rinella","slug":"mary-rinella","institution":"University of Chicago","specialty":"Gastroenterology","url":"https://www.findmykol.com/kol/mary-rinella","json_url":"https://www.findmykol.com/kol/mary-rinella/profile.json"},{"name":"Hedy Kindler","slug":"hedy-kindler","institution":"University of Chicago","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/hedy-kindler","json_url":"https://www.findmykol.com/kol/hedy-kindler/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":36}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-08-07","provider_certified":"2024-08-07","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020}},"methodology_url":"https://www.findmykol.com/about#methodology"}